Next report date
Report period
Q1 2024
EPS estimate
−0.08USD
Revenue estimate
38.92 MUSD
0.06USD
1.25 MUSD
174.56 MUSD
14.34 M
About Pharma Mar SA
Sector
CEO
José Maria Fernández de Sousa-Faro
Headquarters
Colmenar Viejo
Website
Founded
1986
ISIN
ES0169501022
FIGI
BBG00BBVVWC6
Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It operates through the following segments: Oncology, Diagnostics, and RNAi. The Oncology segment focuses to the group undertakings whose object is to research, develop, and market anti-tumour drugs. The Diagnostics segment focuses in the development and marketing of diagnostic kits. The RNAi segment develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was founded by José Maria Fernández de Sousa-Faro on April 30, 1986 and is headquartered in Colmenar Viejo, Spain.
Pharmamar PHMGood morning, today I present the analysis of PHM, a Spanish company pharmamar in the race for the vaccine against Covid19.
It is being a great trading year for this company.
The bullish structure marked by the yellow arrow has been broken, but the new structure, the bearish one, has not yet consoli
Pharmamar may reach 7,06€ +50%It seems that Pharmamar may reach 7,06€ (+50% from current price) after activating an iSHS and improving its rating.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of PHMMF is 26.85 USD — it has decreased by 8.33% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Pharma Mar SA stocks are traded under the ticker PHMMF.
Pharma Mar SA is going to release the next earnings report on Apr 25, 2024. Keep track of upcoming events with our Earnings Calendar.
PHMMF stock is 9.09% volatile and has beta coefficient of 0.73. Check out the list of the most volatile stocks — is Pharma Mar SA there?
PHMMF earnings for the last quarter are 0.08 USD per share, whereas the estimation was 0.23 USD resulting in a −63.64% surprise. The estimated earnings for the next quarter are 0.09 USD per share. See more details about Pharma Mar SA earnings.
Pharma Mar SA revenue for the last quarter amounts to 39.38 M USD despite the estimated figure of 36.93 M USD. In the next quarter revenue is expected to reach 46.14 M USD.
Yes, you can track Pharma Mar SA financials in yearly and quarterly reports right on TradingView.
PHMMF net income for the last quarter is −7.53 M USD, while the quarter before that showed 1.61 M USD of net income which accounts for −568.11% change. Track more Pharma Mar SA financial stats to get the full picture.
Today Pharma Mar SA has the market capitalization of 542.38 M, it has decreased by 3.01% over the last week.
Like other stocks, PHMMF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Pharma Mar SA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Pharma Mar SA technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Pharma Mar SA stock shows the strong sell signal. See more of Pharma Mar SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Pharma Mar SA future price: according to them, PHMMF price has a max estimate of 74.55 USD and a min estimate of 31.52 USD. Read a more detailed Pharma Mar SA forecast: see what analysts think of Pharma Mar SA and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Pharma Mar SA EBITDA is 448.12 K USD, and current EBITDA margin is 0.26%. See more stats in Pharma Mar SA financial statements.